3.29
-0.11 (-3.24%)
| Penutupan Terdahulu | 3.40 |
| Buka | 3.29 |
| Jumlah Dagangan | 67,708 |
| Purata Dagangan (3B) | 179,057 |
| Modal Pasaran | 1,178,594,176 |
| Harga / Pendapatan (P/E Ke hadapan) | 175.44 |
| Harga / Jualan (P/S) | 0.940 |
| Harga / Buku (P/B) | 0.890 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 8 Apr 2026 |
| Margin Keuntungan | -26.26% |
| Margin Operasi (TTM) | -9.91% |
| EPS Cair (TTM) | -0.690 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | -4.20% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 52.48% |
| Nisbah Semasa (MRQ) | 2.03 |
| Aliran Tunai Operasi (OCF TTM) | 34.59 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -90.11 M |
| Pulangan Atas Aset (ROA TTM) | -2.42% |
| Pulangan Atas Ekuiti (ROE TTM) | -20.51% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Drug Manufacturers - Specialty & Generic (US) | Bercampur | Bercampur |
| Drug Manufacturers - Specialty & Generic (Global) | Bercampur | Bercampur | |
| Stok | Evotec SE | Bercampur | Menaik |
AISkor Stockmoo
| Konsensus Penganalisis | NA |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | -2.0 |
| Purata Bergerak Teknikal | -2.5 |
| Osilator Teknikal | -2.5 |
| Purata | -2.33 |
|
Evotec is a drug discovery partnership firm providing solutions to pharmaceutical and biotechnology companies, academic institutions, foundations, and nonprofit organizations. The company offers services in a variety of therapeutic areas, including central nervous system disorders, diabetes, inflammation, oncology, infectious diseases, and women's health. The shared R&D segment, roughly 80% of sales, provides drug discovery and manufacturing services on a typical fee-for-service basis and integrated drug discovery collaborations based on its proprietary, internally developed assets. The Just-Evotec Biologics segment, about 20% of sales, offers CDMO services for biologics. As of 2023, the company has over 5,000 employees and 18 production sites mainly in Europe and the United States. |
|
| Sektor | Healthcare |
| Industri | Drug Manufacturers - Specialty & Generic |
| Gaya Pelaburan | Small Core |
| % Dimiliki oleh Institusi | 2.56% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Abc Arbitrage Sa | 31 Dec 2025 | 554,287 |
| Pitcairn Co | 30 Sep 2025 | 161,769 |
| Old Mission Capital, Llc | 31 Dec 2025 | 51,197 |
| Optiver Holding B.V. | 31 Dec 2025 | 40,603 |
Tiada data dalam julat masa ini.
Tiada data dalam julat masa ini.
| Tarikh | Jenis | Butiran |
|---|---|---|
| 08 Jan 2026 | Pengumuman | Just - Evotec Biologics Receives Grant for AI-Driven Optimization of Monoclonal Antibody Developability for Affordable Access |
| 02 Jan 2026 | Pengumuman | Evotec Appoints Dr. Sarah Fakih as EVP, Head of Global Communications and Investor Relations |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |